Dietmar Rohleder becomes CFO of Haupt Pharma AG
Rohleder takes over as Schwella focuses on production in Berlin
Rohleder takes over responsibility for the areas of finance, accounting and controlling from the previous CFO, Norbert Schwella. As a member of the extended Board committee, Schwella will retain responsibilities for purchasing and IT. In addition, he will be focussing on his role as md of the Group's Berlin production company. Under his leadership, this company has undergone a radical reorganisation over the past two years and today it is Haupt Pharma’s most important site for the production of solid drugs in the OTC segment.
Rohleder has 19 years of working in a wide range of roles in Deutsche Bank's loans and corporate banking business. In 2005 he was appointed to the Board of what is now INVITA AG, where he has been responsible for managing and controlling the holding company ever since.
By appointing Mr Rohleder as the CFO to its holding company Haupt Pharma AG, INVITA AG is demonstrating its support for the strategic path the company is following with the aim of becoming the leading contract manufacturer and developer in Europe.
You may also like
Manufacturing
Avoiding product degradation with a low-temperature, vacuum cake dryer
High-performance chemicals often lose efficacy when exposed to heat. Active pharmaceutical ingredients (APIs), fine chemical intermediates, and biologically derived materials are subject to product degradation and can transform, or lose potency under high drying temperatures. This thermal sensitivity demands precise control to maintain molecular stability and ensure product quality
Manufacturing
Cutting-edge customer projects - Specialised systems for multiple sectors
As specialists in laboratory and process chemistry equipment solutions, Labtex have expertise in designing, manufacturing, and installing customised systems for a diverse range industries and disciplines – including chemical manufacturing, drug development, and metals recovery
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Drug Delivery
AI might find the molecule, but delivery decides whether it becomes a medicine
As the pharmaceutical industry scales AI-driven discovery at unprecedented speed, will the early integration of formulation and manufacturability determine which computationally promising molecules become deliverable medicines?